Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | PRCP | P42785 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19852531 | 0.89 | PDPK1 (0.47) | IDO1PRCPPDPK1 | |
| SCHEMBL3296406 | 0.85 | IDO1 (0.49) | IDO1PRCPCHRNA7PDPK1GID4 | |
| SCHEMBL3000155 | 0.85 | IDO1 (0.49) | IDO1PRCPCHRNA7PDPK1GID4 | |
| SCHEMBL15540606 | 0.82 | IDO1 (0.50) | IDO1PRCPCHRNA7PDPK1GID4 | |
| SCHEMBL13006752 | 0.82 | IDO1 (0.50) | IDO1PRCPCHRNA7PDPK1GID4 | |
| Hydrogen Peroxide SCHEMBL9456544 | 0.82 | IDO1 (0.46) | IDO1PRCPTSHR | |
| SCHEMBL3000325 | 0.79 | IDO1 (0.44) | IDO1PRCPCHRNA7 | |
| SCHEMBL29463951 | 0.79 | IDO1 (0.44) | IDO1PRCPCHRNA7 | |
| SCHEMBL5549328 | 0.79 | IDO1 (0.44) | IDO1PRCP | |
| SCHEMBL23075878 | 0.78 | IDO1 (0.42) | IDO1PRCPTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7488748-B2 | 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2009-02-10 | — | — | US | disclosed |
| US-20060247225-A1 | 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2006-11-02 | — | — | US | disclosed |
| EP-1590325-A1 | 3,6-DISUBSTITUTED AZABICYCLO HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES, LTD. (IN) | 2005-11-02 | — | — | EP | disclosed |
| WO-2004067510-A1 | 3,6-DISUBSTITUTED AZABICYCLO HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247225-A1 | 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists | CHRM3, CHRM5, CHRM2 | IDO1 466/4885PRCP 4393/4885CHRNA7 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.